切换至 "中华医学电子期刊资源库"

中华危重症医学杂志(电子版) ›› 2021, Vol. 14 ›› Issue (03) : 217 -221. doi: 10.3877/cma.j.issn.1674-6880.2021.03.008

短篇论著

局部晚期直肠癌术前同步放射治疗及化学治疗联合热疗67例疗效分析
刘卓1, 陶金华1, 沈金闻2, 李德川1, 朱玉萍1, 罗加林2,()   
  1. 1. 310022 杭州,中国科学院大学附属肿瘤医院(浙江省肿瘤医院)结直肠肿瘤外科;310022 杭州,中国科学院大学附属肿瘤医院(浙江省肿瘤医院)中国科学院肿瘤与基础研究所
    2. 310022 杭州,中国科学院大学附属肿瘤医院(浙江省肿瘤医院)中国科学院肿瘤与基础研究所;310022 杭州,中国科学院大学附属肿瘤医院(浙江省肿瘤医院)腹部肿瘤放疗科
  • 收稿日期:2021-05-01 出版日期:2021-06-30
  • 通信作者: 罗加林
  • 基金资助:
    浙江省医药卫生科技计划项目(2018KY305); 浙江省自然科学基金项目(Y19H160049)

Clinical analysis of 67 patients with locally advanced rectal cancer treated with preoperative synchronous radiotherapy and chemotherapy combined with hyperthermia

Zhuo Liu1, Jinhua Tao1, Jinwen Shen2   

  • Received:2021-05-01 Published:2021-06-30
引用本文:

刘卓, 陶金华, 沈金闻, 李德川, 朱玉萍, 罗加林. 局部晚期直肠癌术前同步放射治疗及化学治疗联合热疗67例疗效分析[J]. 中华危重症医学杂志(电子版), 2021, 14(03): 217-221.

Zhuo Liu, Jinhua Tao, Jinwen Shen. Clinical analysis of 67 patients with locally advanced rectal cancer treated with preoperative synchronous radiotherapy and chemotherapy combined with hyperthermia[J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2021, 14(03): 217-221.

目的

探讨局部晚期直肠癌(LARC)患者术前同步放射治疗及化学治疗联合热疗的临床疗效。

方法

选取2009年7月至2013年12月在浙江省肿瘤医院确诊为LARC(美国癌症联合委员会分期T3 ~ T4伴或不伴淋巴结转移)的67例患者为研究对象,行术前新辅助放射治疗及化学治疗联合热疗,放射治疗总剂量为50 Gy,放射治疗前1 h内进行热疗(每周2次),持续5周。放射治疗结束4 ~ 6周后对LARC患者进行手术治疗。对所有患者的临床疗效进行评价,并采用Kaplan-Meier绘制生存曲线进行分析。

结果

67例患者中共64例患者接受手术治疗,且均恢复顺利出院;余3例因拒绝切除肛门而放弃手术治疗。96.9%(62 / 64)的患者达到R0切除,89.1%(57 / 64)的患者出现局部降期,23.4%(15 / 64)的患者病理完全缓解(pCR),76.6%(49 / 64)的患者病理示无淋巴结转移(ypN-),Ⅲ级不良反应发生率为14.9%(10 / 67)。术后随访3 ~ 72个月,5年总生存率为81.2%(52 / 64),5年肿瘤无病生存率为70.3%(45 / 64)。同时,pCR患者的生存曲线明显优于非pCR患者( χ2 = 4.132,P = 0.042),ypT0 ~ T2患者的生存曲线明显优于ypT3 ~T4患者( χ2 = 14.791,P < 0.001),ypN-患者的生存曲线明显优于ypN+患者( χ2 = 12.402,P < 0.001)。

结论

新辅助放射治疗及化学治疗联合热疗治疗LARC可以显著提高LARC患者的pCR、R0切除率及保肛率,肿瘤退缩明显,且不会增加治疗相关不良反应,患者耐受性较好。

表1 术前同步放射治疗及化学治疗联合热疗后肿瘤局部降期情况(例)
1
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66 (2): 115-132.
2
Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28 (suppl 4): iv22-iv40.
3
Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study[J]. Lancet Oncol, 2014, 15 (2): 184-190.
4
Capirci C, Valentini V, Cionini L, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients[J]. Int J Radiat Oncol Biol Phys, 2008, 72 (1): 99-107.
5
Rau B, Wust P, Tilly W, et al. Preoperative radiochemotherapy in locally advanced or recurrent rectal cancer: regional radiofrequency hyperthermia correlates with clinical parameters[J]. Int J Radiat Oncol Biol Phys, 2000, 48 (2): 381-391.
6
Gani C, Lamprecht U, Ziegler A, et al. Deep region-al hyperthermia with preoperative radiochemotherapy in locally advanced rectal cancer, a prospective phase Ⅱ trial[J]. Radiother Oncol, 2021 (159): 155-160.
7
Zwirner K, Bonomo P, Lamprecht U, et al. External validation of a rectal cancer outcome prediction model with a cohort of patients treated with preoperative radiochemotherapy and deep regional hyperthermia[J]. Int J Hyperthermia, 2018, 34 (4): 455-460.
8
Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual[M]. 7th ed. New York: Springer-Verlag, 2009: 117-126.
9
Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment[J]. Semin Radiat Oncol, 2003, 13 (3): 176-181.
10
Rau B, Wust P, Hohenberger P, et al. Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer: a phase Ⅱ clinical trial[J]. Ann Surg, 1998, 227 (3): 380-389.
11
Benson AB, Venook AP, Al-Hawary MM, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2018, 16 (7): 874-901.
12
Lee WS, Baek JH, Shin DB, et al. Neoadjuvant treatment of mid-to-lower rectal cancer with oxaliplatin plus 5-fluorouracil and leucovorin in combination with radiotherapy: a Korean single center phase Ⅱ study[J]. Int J Clin Oncol, 2013, 18 (2): 260-266.
13
Li Y, Wang J, Ma X, et al. A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J]. Int J Bio Sci, 2016, 12 (8): 1022-1031.
14
Smith JJ, Garcia-Aguilar J. Advances and challenges in treatment of locally advanced rectal cancer[J]. J Clin Oncol, 2015, 33 (16): 1797-1808.
15
Minsky BD, Cohen AM, Kemeny N, et al. Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable recta cancer[J]. Int J Radiat Oncol Biol Phys, 1993, 25 (5): 821-827.
16
Arjona-Sánchez A, Barrios P, Boldo-Roda E, et al. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma[J]. BMC Cancer, 2018, 18 (1): 183.
17
Shoji H, Motegi M, Osawa K, et al. A novel strategy of radiofrequency hyperthermia (neothermia) in combination with preoperative chemoradiotherapy for the treatment of advanced rectal cancer: a pilot study[J]. Cancer Med, 2015, 4 (6): 834-843.
18
Kang MK, Kim MS, Kim JH. Clinical outcomes of mild hyperthermia for locally advanced rectal cancer treated with preoperative radiochemotherapy[J]. Int J Hyperthermia, 2011, 27 (5): 482-490.
19
Maluta S, Romano M, Dall'oglio S, et al. Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum[J]. Int J Hyperthermia, 2010, 26 (2): 108-117.
20
Tsutsumi S, Tabe Y, Fujii T, et al. Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy[J]. Anticancer Res, 2011, 31 (11): 3963-3967.
21
van der Zee J, González González D, van Rhoon GC, et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group[J]. Lancet, 2000, 355 (9210): 1119-1125.
22
van der Valk MJM, Marijnen CAM, van Etten B, et al. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer-results of the international randomized RAPIDO-trial[J]. Radiother Oncol, 2020 (147): 75-83.
23
Asao T, Sakurai H, Harashima K, et al. The synchronization of chemotherapy to circadian rhythms and irradiation in pre-operative chemoradiation therapy with hyperthermia for local advanced rectal cancer[J]. Int J Hyperthermia, 2006, 22 (5): 399-406.
[1] 任书堂, 刘晓程, 张亚东, 孙佳英, 陈萍, 周建华, 龙进, 黄云洲. 左心室辅助装置支持下单纯收缩期主动脉瓣反流的超声心动图特征[J]. 中华医学超声杂志(电子版), 2023, 20(10): 1023-1028.
[2] 伊喆, 王志新, 陈伟, 齐伟亚, 方杰, 石海飞, 赵夏, 赵喆, 竺枫, 盛伟, 陈焱, 张宇昊, 朱瑾, 殷耀斌, 杨勇, 陈山林, 刘波. 机器人辅助无移位急性舟骨骨折经皮内固定的诊疗与手术操作规范[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 464-468.
[3] 刘竹影, 周年苟, 李泳祺, 周丽斌. 空心环钻联合手术导板用于自体牙移植牙槽窝备洞[J]. 中华口腔医学研究杂志(电子版), 2023, 17(06): 418-423.
[4] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[5] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[6] 张焱辉, 张蛟, 朱志贤. 留置肛管在中低位直肠癌新辅助放化疗后腹腔镜TME术中的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 25-28.
[7] 李婷, 张琳. 血清脂肪酸代谢物及维生素D水平与结直肠癌发生的关系研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 661-665.
[8] 付振保, 曹万龙, 刘富红. 腹腔镜直肠癌低位前切除术中不同缝合方法的回肠双腔造口术临床效果研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 684-687.
[9] 贺亮, 王松林, 周业江. 两种预防性回肠造口在腹腔镜ISR术治疗超低位直肠癌的效果对比研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 697-700.
[10] 刘成, 赖聪, 黄健, 王建辰, 罗茜芸, 许可慰. EDGE SP1000单孔手术机器人辅助腹腔镜下猪输尿管部分切除联合端端吻合术的可行性研究[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 642-646.
[11] 倪文凯, 齐翀, 许小丹, 周燮程, 殷庆章, 蔡元坤. 结直肠癌患者术后发生延迟性肠麻痹的影响因素分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 484-489.
[12] 范小彧, 孙司正, 鄂一民, 喻春钊. 梗阻性左半结肠癌不同手术治疗方案的选择应用[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 500-504.
[13] 杨红杰, 张智春, 孙轶. 直肠癌淋巴结转移诊断研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 512-518.
[14] 马慧颖, 凡新苓, 覃仕瑞, 陈佳赟, 曹莹, 徐源, 金晶, 唐源. 磁共振加速器治疗局部晚期直肠癌的初步经验[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 519-523.
[15] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
阅读次数
全文


摘要